A Study on Vonoprazan in the Real-world Clinical Practice in China

NCT04501627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-10-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of Vonoprazan by assessing all adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs) in routine clinical settings in China.

Conditions

  • Esophagitis Peptic

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-24
Primary Completion
2023-06-27
Completion
2023-06-27

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501627 on ClinicalTrials.gov